JW Pharmaceutical Corp Cash Flow-to-Debt Ratio
JW Pharmaceutical Corp cash flow-to-debt ratio. JW Pharmaceutical Corp (001065) has a Cash Flow-to-Debt Ratio of 0.17x as of June 2026, meaning its operating cash flow of ₩42.51 Billion could theoretically repay 0% of its total liabilities (₩249.96 Billion) in one year. Check JW Pharmaceutical Corp cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of JW Pharmaceutical Corp (2014–2025)
Cash flow-to-debt ratio of JW Pharmaceutical Corp from 2014 to 2025. Historical debt coverage capacity for JW Pharmaceutical Corp across 12 annual periods. Check JW Pharmaceutical Corp cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
JW Pharmaceutical Corp Cash Flow-to-Debt Ratio by Year (2014–2025)
JW Pharmaceutical Corp cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for JW Pharmaceutical Corp. For the full cash flow conversion analysis, see JW Pharmaceutical Corp (001065) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.41x | ₩96.40 Billion | ₩235.90 Billion | ▲ +41.6% |
| 2024 | 0.29x | ₩79.39 Billion | ₩275.11 Billion | ▲ +25.7% |
| 2023 | 0.23x | ₩87.16 Billion | ₩379.60 Billion | ▲ +62.7% |
| 2022 | 0.14x | ₩56.76 Billion | ₩402.21 Billion | ▲ +246.1% |
| 2021 | 0.04x | ₩18.12 Billion | ₩444.51 Billion | ▼ -77.9% |
| 2020 | 0.18x | ₩63.05 Billion | ₩341.62 Billion | ▲ +14.0% |
| 2019 | 0.16x | ₩55.53 Billion | ₩343.12 Billion | ▲ +3.6% |
| 2018 | 0.16x | ₩52.11 Billion | ₩333.68 Billion | ▲ +68.1% |
| 2017 | 0.09x | ₩33.45 Billion | ₩360.10 Billion | ▲ +416.6% |
| 2016 | 0.02x | ₩6.74 Billion | ₩374.76 Billion | ▲ +267.1% |
| 2015 | -0.01x | ₩-4.17 Billion | ₩388.07 Billion | ▼ -154.6% |
| 2014 | 0.02x | ₩7.28 Billion | ₩369.22 Billion | — |